Abstract / Description of output
Enfuvirtide is the first member of the fourth class of antiretroviral drugs to become available. We present a case report of a human immunodeficiency virus (HIV)-positive patient with mild renal impairment who developed severe renal impairment secondary to tenofovir therapy while receiving enfuvirtide. Because the patient's pharmacokinetic profile was not significantly altered, compared with that of HIV-infected patients with normal renal function, no dose modifications were required.
Original language | English |
---|---|
Pages (from-to) | e119-21 |
Journal | Clinical Infectious Diseases |
Volume | 39 |
Issue number | 11 |
DOIs | |
Publication status | Published - 1 Dec 2004 |
Keywords / Materials (for Non-textual outputs)
- Adult
- HIV Envelope Protein gp41
- HIV Fusion Inhibitors
- HIV Seropositivity
- Humans
- Kidney Diseases
- Male
- Peptide Fragments